Skip to main content
OpenTrials
Completed

NCT Number: NCT02868645

Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia

Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bone Fibrous Dysplasia Bone Diseases Bone Diseases, Developmental Fibrous Dysplasia of Bone Musculoskeletal Diseases Osteochondrodysplasias

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service de rhumatologie Pavillon F - Hôpital Edouard Herriot

Lyon, 69437, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with fibrous dysplasia of the bone
  • access to social security
  • informed consent

Exclusion criteria

  • no informed consent
  • pregnancy
  • patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis…)

Treatment and study plan

Blood sampling

Biological

Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum

Primary outcomes

  1. Periostin rate in serum

    Time frame: At inclusion

Secondary outcomes

  1. Periostin rate in serum according to the number of fibrotic bones

    Time frame: At inclusion

  2. Periostin rate in serum in patients with severe phenotype of the disease

    Time frame: At inclusion

  3. Periostin rate in serum in patients with Mac Cune Albright syndrome

    Time frame: At inclusion

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: PERIOSTINE

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Aug 16, 2016
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.